Share Hub

Spartina (Tirzepatide) in the Chair: What to Ask and What to Change

Spartina is Iran's most-used weekly injectable weight-loss drug. Its active ingredient is tirzepatide. The same molecule is sold worldwide under the name Mounjaro for type 2 diabetes and Zepbound for obesity.

Tirzepatide mimics the effect of two natural gut hormones that are released after a meal: they reduce appetite, increase insulin secretion, and slow gastric emptying. The last three effects are exactly where this concerns us.

Given how common the drug is right now, there is a high chance that a patient in your chair is taking Spartina. The problem is that many patients don't mention it in their history, because they don't think of it as a "medication" — they think of it as a weight-loss item.

∆ Source of this article

The figures in this article are based on the official prescribing information for Zepbound — the full, detailed label that the manufacturer (Eli Lilly) writes and the FDA approves and publishes. The version used is the December 2024 revision.

The adverse-event data in this label come from two clinical trials, introduced in the label as Study 1 and Study 2 — in fact the SURMOUNT-1 and SURMOUNT-2 trials. Both were randomized, double-blind, placebo-controlled, ran 72 weeks, and enrolled roughly 3,400 patients combined. Links to both are at the end of this article so you can check them yourself.

An honest note about Spartina itself: we have no independent clinical data on Spartina. Our assumption is that because the active ingredient is identical, the adverse effects will be similar too. That assumption is reasonable, but untested — no study is available showing that Spartina delivers exactly the same amount of drug into the blood at the same rate. On top of that, the figures below come from obesity trials. A patient taking tirzepatide for diabetes is a different patient, and their adverse-event figures can differ too.

∆ Questions to ask in the medical history

Asking "are you taking any medication?" is not enough. Four specific questions:

1. Do you take a weekly injection for weight loss or blood sugar? What is it called?
2. How long have you been on it, and has your dose gone up recently?
3. Do you have nausea, vomiting, or heartburn?
4. Are you also taking insulin or a blood-sugar pill alongside it?

Question two matters more than it looks. This drug starts at 2.5 mg and increases by 2.5 mg every four weeks until it reaches a fixed maintenance dose (5, 10, or 15 mg). This titration period lasts about 20 weeks, and most gastrointestinal adverse effects happen precisely during this period and then decrease. So a patient whose dose went up three weeks ago and a patient who has been on a stable dose for a year are two different patients.

∆ 1. Sedation and anesthesia: the most important point for us

This is the only section that was added in the label's most recent revision (October 2024), and it has the most direct relevance to dentistry.

Tirzepatide slows gastric emptying. There are rare reports of patients on this class of drug who went for elective surgery under general anesthesia or deep sedation, fully complied with fasting instructions, and still had a non-empty stomach, with gastric contents entering the lungs.

The critical point is that the label explicitly states there is insufficient data to recommend extending the fasting period or temporarily stopping the drug. In other words, you are not authorized to stop the drug yourself, and you cannot reassure yourself just by adding a few extra hours of fasting. The correct approach is:

In any case involving deep sedation or general anesthesia (extensive surgeries, multiple implants, treating children and patients with special needs), identify Spartina use before booking the appointment
Explicitly inform the anesthesiologist and leave the decision about fasting or stopping the drug to them
This warning is not relevant for light sedation or nitrous oxide

∆ 2. Erosion: more of a concern than dry mouth

If we had to pull just one dental risk out of this label, it would not be dry mouth:

Vomiting in 8 to 13 percent of patients (dose-dependent), versus 2 percent on placebo
Gastroesophageal reflux in 4 to 5 percent, versus 2 percent
Nausea in 25 to 29 percent, versus 8 percent

In terms of scale, repeated contact of enamel with stomach acid is several times more common than any saliva-related scenario. On examination, look for erosion of the palatal surfaces of the upper anterior teeth and cupping of occlusal surfaces, especially in patients who are in the dose-titration period.

Patient education for this period is straightforward: don't brush immediately after vomiting, rinse the mouth with water or a baking-soda solution, and delay brushing by at least half an hour. High-concentration topical fluoride is reasonable in a patient with active erosion.

∆ 3. Hypoglycemia in the chair

In the diabetic-patient trial, blood glucose below 54 was reported in 4.2 percent of the drug group versus 1.3 percent on placebo. But the key figure is this: in patients also taking a sulfonylurea (like glyburide), this rate reached 10.3 percent, versus 2.1 percent in everyone else.

So Spartina alone does not carry a striking hypoglycemia risk, but Spartina plus glyburide or insulin is a high-risk patient. For this group, avoid long early-morning fasting appointments, keep fast-acting sugar on hand, and stay alert to hypoglycemia symptoms during treatment.

Low blood pressure was also reported in 1.6 percent of patients, rising to 2.2 percent in patients on blood-pressure medication. Remind patients to get up from the chair gradually.

∆ 4. The analgesic you prescribe after treatment

Spartina slows gastric emptying. Every oral tablet also has to pass from the stomach into the intestine to be absorbed, so as emptying slows, the drug's arrival in the bloodstream is delayed.

The label measured this with acetaminophen: peak effect arrived one hour later, and at that moment blood concentration was 55 percent lower than normal. But the total amount of drug absorbed over 24 hours did not change. This effect was also temporary and was no longer seen after a few weeks.

In plain terms: the total analgesic reaching the patient does not decrease, but it may act later, mainly in the first weeks of treatment or right after a dose increase. For post-surgical pain control, it makes sense to start the analgesic earlier, before the local anesthetic wears off, to cover this delay.

∆ 5. Direct oral adverse effects: low prevalence but worth knowing

None of the following reached the 2 percent threshold required for inclusion in the main common-adverse-effects table:

Dry mouth or throat: 1 percent versus 0.1 percent on placebo. This figure is combined — dry mouth and dry throat are counted together — so dry mouth alone is worth even less than 1 percent.

Taste disturbance: 0.4 percent versus zero on placebo.

Abnormal sensation and paresthesia (dysesthesia): 0.2 to 0.4 percent versus 0.1 percent on placebo. The label does not say where on the body. If a patient complains of a vague tingling in the lip or tongue, keep this in mind, but rule out the more common causes first.

Allergic reactions: rapid reactions (within one day of injection) in 2.1 percent versus 0.4 percent on placebo, most of which were simply hives and skin itching. Severe reaction in 0.1 percent. Cases of anaphylaxis and swelling of the face, lips, tongue, and throat appear only in the "post-marketing reports" section. The label itself states that these reports are voluntary, their true prevalence cannot be calculated, and it is not certain the drug was necessarily at fault.

Neck examination: this drug caused thyroid tumors in mice, and it is not known whether the same holds in humans. Independent of this, every patient is told to inform their physician if they notice a neck mass, persistent hoarseness, difficulty swallowing, or shortness of breath. If you come across anything like this during a routine head-and-neck exam, refer the patient.

∆ How seriously should we take these numbers?

A point that's easy to miss: the fact that a number comes out of a good clinical trial does not, by itself, make it valid. What matters is whether the study was actually looking for that variable at all.

These trials were not designed to measure oral status. Their goal was weight loss. Oral adverse effects were recorded only because the patient raised a complaint at a visit, which was then coded. There was no measurement of salivary flow, no targeted dry-mouth questionnaire, and no standardized taste test. The sample size is also not large enough to detect a difference in adverse effects with a prevalence under 1 percent.

Practical takeaway: these figures are useful for estimating the general size of the problem, not for proving or disproving a fine-grained cause-and-effect relationship.

∆ Clinical perspective

From here on this is reasoning, not a documented finding in the label. We are keeping that distinction deliberate.

First, a distinction has to be drawn between the subjective feeling of dry mouth (xerostomia) and an actual, measured reduction in salivary flow. The label only records the patient's own complaint and has no data on salivary flow rate. So you cannot conclude from this label that tirzepatide reduces salivary flow. If a patient complains of dry mouth, rather than pinning it directly on Spartina, first measure salivary flow and review their other xerostomic medications.

Second, caries is a multifactorial phenomenon that depends above all on the frequency of tooth contact with fermentable carbohydrate, not on total caloric intake. The label shows this drug reduces caloric intake, but has no data on the pattern or frequency of sugar consumption. That a change in diet might have a protective role is a reasonable guess, not a finding. A firm conclusion in either direction does not follow from this label.

Third, if a genuine reduction in saliva were documented in a particular patient, the consequences are predictable. Saliva plays a role in forming the seal and stability of a removable prosthesis, and a change in its concentration or volume can worsen denture retention and patient comfort. In implant patients, especially where keratinized gingiva is limited, disruption of the mouth's normal self-cleansing can speed up plaque accumulation and shorten recall intervals. This chain has not been examined in the label and is raised purely on the basis of saliva's known role.

∆ Summary

Direct oral adverse effects of tirzepatide have a low prevalence and are not, on their own, a major threat to teeth. But that means there's little reason to worry about caries specifically — not that Spartina use is a trivial line item in the chart. Three things, if the answer is yes, actually change what you do:

Deep sedation or general anesthesia is planned: be sure to tell the anesthesiologist, and don't stop the drug yourself
The patient is in the dose-titration period and has vomiting or reflux: assess for erosion, give post-vomiting instructions, apply topical fluoride
They're also taking insulin or a sulfonylurea: plan appointment timing and be ready for hypoglycemia

Everything else is adequately covered by ordinary awareness and a watchful routine exam.